ABVX
Abivax S.A.
NASDAQ · Healthcare · Biotechnology · FR
$114.88
+0.74%Jul 16, 2026, 14:25 UTC
Abivax raised $920 million in a capital raise to fund operations into Q4 2029.
Source:Jul 10, 2026, 10:10 UTC
Abivax raised $920 million in a funding round to finance a solo U.S. launch of its bowel disease drug.
Source:Jul 1, 2026, 05:30 UTC
Abivax SA requested a temporary halt of trading of its ordinary shares on Euronext Paris, effective from market opening at 9:00 a.m. on July 1, 2026.
Source:Jul 1, 2026, 04:56 UTC
Abivax shares surged over 38% on June 30, 2026, after new Phase 3 data eased cancer-safety fears.
Source:Jun 30, 2026, 20:45 UTC
Abivax SA launched an underwritten public offering of approximately $600 million of its American Depositary Shares in the United States.
Jun 30, 2026, 17:16 UTC
Abivax SA released updated safety data from its late-stage ulcerative colitis program for obefazimod.
Jun 2, 2026, 13:51 UTC
ABIVAX Société Anonyme announced positive Phase III ABTECT trial results for obefazimod in ulcerative colitis.
Jun 2, 2026, 08:45 UTC
Abivax reported adverse events in a late-stage clinical trial for its bowel-disease drug, with some patients developing cancer unrelated to the treatment.
Source:Jun 2, 2026, 08:21 UTC
Abivax shares tumbled after the company reported late-stage data for its experimental inflammatory bowel drug, with investors focusing on safety concerns.